MedTrace Logo

Treating Peritoneal Carcinomatosis With PIPAC

NCT02320448 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2017-09-12

No results posted yet for this study

Summary

This is a feasibility study that aims to evaluate whether PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) is a safe and feasible treatment in Danish patients with peritoneal cancer.

Conditions

  • Peritoneal Carcinomatosis

Interventions

DRUG

PIPAC

Sponsors & Collaborators

  • Michael Bau Mortensen

    lead OTHER

Principal Investigators

  • Michael Mortensen, Professor · Odense University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02320448 on ClinicalTrials.gov